|
|
| Begins |
September 29, 2003
|
|
|
|
|
|
|
|
| Email |
jlin@srinstitute.com
|
|
|
|
|
|
|
|
|
| Contact |
333 Seventh Avenue
New York, NY 10001
|
|
|
|
|
|
| Description |
Over the past decade, a much more complete understanding of the complexity of classical nuclear hormone receptor signaling has emerged. This growing knowledge serves as a basis for revitalizing drug discovery approaches for these “old targets.” In particular, the finding that multiple signaling mechanisms can underlie nuclear receptor-mediated physiology, and that nuclear receptor ligands act through these mechanisms selectively, and in a tissue-specific manner, makes the notion of side-effect free nuclear receptor therapeutics seem like a distinct possibility. Learn from leading pharmaceutical industry experts and take the opportunity to discuss new research with the experts.
PARTICIPANTS INCLUDE:
AstraZeneca
Bayer Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly & Company
Incyte San Diego
J&J Pharmaceutical R&D
Karo Bio USA
Locus Pharmaceuticals
Merck Research Labs
National Cancer Institute
National Institutes of Health
Panvera Corporation
Pfizer Global R&D
Sangamo Biosciences
Schering Plough
Van Andel Research Institute
X-Ceptor Therapeutics
KEYNOTE PRESENTATIONS:
The Human Glucocorticoid Receptor: Molecular Mechanisms Controlling the Termination of Glucocorticoid Responses
John A. Cidlowski, Ph.D., Chief of Laboratory of Signal Transduction
NATIONAL INSTITUTES OF HEALTH
Vitamin D Receptor: A Drug Discovery Target of the Nuclear Receptor Superfamily
Sunil Nagpal, Ph.D., Group Leader, Gene Regulation Bone Research & Enabling Technology
ELI LILLY & COMPANY
|
|
|
|
